FDA Approves Novel Glucose Monitoring System
The Food and Drug Administration yesterday approved the first continuous glucose monitoring system with a fully implantable sensor, designed to measure glucose levels in adults with diabetes for up to 90 days. Once implanted under the skin during an outpatient procedure, the sensor sends information to a mobile app to alert users if glucose levels are too high or too low. “The FDA is committed to advancing novel products that leverage digital technology to improve patient care,” said FDA Commissioner Scott Gottlieb, M.D.
Related News Articles
Chairperson's File
This week brings the fourth week of the federal government shutdown as Congress has yet to pass legislation to fund the government. This shutdown is a bit…
Headline
Members of the AHA Board of Trustees Oct.14 participated in a panel on the future of rural health care during the Sanford Rural Health Summit in Sioux Falls, S…
Headline
The AHA detailed its key health care priorities for the remainder of the year in comments to House and Senate majority and minority leaders Sept. 15. The AHA…
Headline
The AHA commented Sept. 12 on the Centers for Medicare & Medicaid Services calendar year 2026 physician fee schedule proposed rule. The AHA applauded CMS…
Chairperson's File
The recently enacted One Big Beautiful Bill Act will bring big changes to health care. AHA President and CEO Rick Pollack joined me for a Leadership Dialogue…
Headline
The AHA May 12 responded to the Office of Management and Budget's April 11 request for information on regulatory relief, making 100 suggestions to the Trump…